Clinical trials: sponsored by Ipsen
Breast Neoplasms
A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth
This study is investigating the effects of a new hormone treatment for breast cancer called Irosustat. Seventy percent of breast cancers in post-menopausal wome rely on oestrogen to grow therefore are likely to respond to hormone…
- Trial name
- IPET (NCT01662726)
- Testing
- Irosustat
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Imperial College London
Fertility Preservation, Alkylating Agents
Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure
Chemotherapy drugs like alkylating agents are frequently used in various combined regimens to treat neoplastic and benign diseases.
- Conditions
- Fertility Preservation, Alkylating Agents, Lymphoma
- Trial name
- Erasme-POF (NCT01160315)
- Testing
- Triptorelin, Norethisterone acetate
- Where
- 15 sites in Belgium, France and 1 more
- Volunteers
- 118 people
- Sponsor
- Erasme University Hospital
Tourette Syndrome, Chronic Vocal Tic
Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome
Our intervention will be the injection of Abobotulinum toxin A into the affected site/vocal cords for patients with the diagnosis of Primary Tourette's syndrome.
- Trial name
- NCT02187679
- Testing
- Abobotulinum toxin A
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Detroit Clinical Research Center
Polycystic Liver Disease
Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
The aim of this study is to determine the effect of Lanreotide on polycystic liver and kidneys in patients with autosomal dominant polycystic kidney disease.
- Trial name
- RESOLVE (NCT01354405)
- Testing
- Lanreotide
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- Radboud University Medical Center
Polycystic Liver Disease
Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease, including a dose escalation at month 6 to lanreotide…
- Trial name
- LOCKCYST (NCT01315795)
- Testing
- Lanreotide Autogel 90 mg and 120 mg
- Where
- Belgium
- Volunteers
- 59 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Risk of Bone Fracture Occurrences
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.
- Trial name
- TREAT2 (NCT01214291)
- Testing
- Toremifene
- Where
- United States
- Sponsor
- GTx
Lymphocele
Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer
Injection the day before surgery of 90 mg of Lanreotide LP sub-cutaneously or placebo. Evaluation of the lymphorrhea in the 2 arms of the study
- Trial name
- NCT00630695
- Testing
- Lanreotide LP 90
- Where
- France
- Volunteers
- 148 people
- Sponsor
- University Hospital, Limoges
Polycystic Liver Disease, Hepatomegaly
Lanreotide as Treatment of Polycystic Livers
To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed.
- Conditions
- Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Polycystic Kidney, Autosomal Dominant
- Trial name
- LOCKCYST (NCT00565097)
- Testing
- Lanreotide
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 38 people
- Sponsor
- Radboud University Medical Center
Polycystic Liver Disease, Hepatomegaly
Open-Label Extension of LOCKCYST Trial
Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%.
- Conditions
- Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Polycystic Kidney
- Trial name
- LOCKCYST-ext (NCT00771888)
- Testing
- lanreotide
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 54 people
- Sponsor
- Radboud University Medical Center
Hemophilia A
Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII
The ability of a new recombinant porcine coagulation factor VIII, B-domain deleted (called "OBI-1"), to control the non-life- or limb-threatening bleeding episodes patients with hemophilia A commonly develop is being evaluated.
- Trial name
- NCT00245245
- Testing
- recombinant porcine coagulation factor VIII (OBI-1)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Octagen Corporation